Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
Frankie Ann Holmes, Joyce O’Shaughnessy, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2002
PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 microg/kg) is as safe and effective as daily filgrastim (5 microg/kg/d) for reducing neutropenia in patients who received four cycles of myelosuppressive chemotherapy. PATIENTS AND METHODS: Sixty-two centers enrolled 310 patients who received chemotherapy with docetaxel 75 mg/m(2) and doxorubicin 60 mg/m(2) on day 1 of each cycle for a maximum of four cycles. Patients were randomized to receive on day 2 either a single subcutaneous injection of pegfilgrastim 100 microg/kg per chemotherapy cycle (154 patients) or daily subcutaneous injections of filgrastim 5 microg/kg/d (156 patients). Absolute neutrophil count (ANC), duration of grade 4 neutropenia, and safety parameters were monitored. RESULTS: One dose of pegfilgrastim per chemotherapy cycle was comparable to daily subcutaneous injections of filgrastim with regard to all efficacy end points, including the duration of severe neutropenia and the depth of ANC nadir in all cycles. Febrile neutropenia across all cycles occurred less often in patients who received pegfilgrastim. The difference in the mean duration of severe neutropenia between the pegfilgrastim and filgrastim treatment groups was less than 1 day. Pegfilgrastim was safe and well tolerated, and it was similar to filgrastim. Adverse event profiles in the pegfilgrastim and filgrastim groups were similar. CONCLUSION: A single injection of pegfilgrastim 100 microg/kg per cycle was as safe and effective as daily injections of filgrastim 5 microg/kg/d in reducing neutropenia and its complications in patients who received four cycles of doxorubicin 60 mg/m(2) and docetaxel 75 mg/m(2).
Cited by 537 works. doi:10.1200/jco.20.3.727
Authors
- Frankie Ann Holmes
- Joyce O’Shaughnessy
- Svetislava J. Vukelja
- Stephen E. Jones
- Jeffrey C. Shogan
- John A. Glaspy
- Malcolm A.S. Moore
- Luis Alfredo Meza
- Israel Wiznitzer
- Theresa Neumann
- Lister Hill
- Bertrand C. Liang
References
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
- EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
- GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION
- Filgrastim (r-metHuG-CSF): the first 10 years
- Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy
- A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans
- Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study